Recent developments in new and old viral infections.

Area of Science:

• Hematology
• Infectious Diseases
• Immunology

Background:

• Viral infections and hematologic malignancies were historically linked to allogeneic stem cell transplantation.
• Recent advancements in treating hematologic malignancies involve immunomodulatory agents like monoclonal antibodies (e.g., anti-CD20, anti-CD52).
• These therapies target lymphocyte antigens, significantly influencing viral infection dynamics in patients.

Purpose of the Study:

• To highlight the impact of immunomodulatory agents on viral infections in patients with hematologic malignancies.
• To discuss the mechanisms of viral acquisition and endogenous reactivation.
• To emphasize the evolving landscape of viral threats, including emerging infections.

Main Methods:

• Review of current literature on viral infections in hematologic malignancy patients.
• Analysis of the role of immunomodulatory agents in altering viral infection patterns.
• Identification of common and emerging viral pathogens of concern.

Main Results:

• Immunomodulatory therapies increase the incidence, severity, and alter the timing of viral infections.
• Viral infections can arise from transfusion, community exposure, donor origin, or reactivation of latent viruses.
• Herpesviruses remain a primary concern, with emerging viral infections gaining significance.

Conclusions:

• Monoclonal antibodies and other immunomodulatory agents significantly alter the risk profile for viral infections in hematologic malignancy patients.
• Viral infections pose direct threats and indirect risks, including opportunistic infections and reduced survival.
• Continuous monitoring and awareness of both traditional and emerging viral infections are crucial for patient management.